TXTM (ProText Mobility) EV-to-FCF: -60.39 (As of Jun. 27, 2026)


What is ProText Mobility EV-to-FCF?

ProText Mobility TXTM -3.00% EV-to-FCF is -60.39 as of Jun. 27, 2026.

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ProText Mobility's Enterprise Value is $42.64 Mil. ProText Mobility's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2014 was $-0.71 Mil. Therefore, ProText Mobility's EV-to-FCF for today is -60.39.

The historical rank and industry rank for ProText Mobility's EV-to-FCF or its related term are showing as below:

TXTM' s EV-to-FCF Range Over the Past 10 Years
Min: -68.49   Med: 0   Max: 0
Current: -60.4

TXTM's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 14.65 vs TXTM: -60.40

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-06-27), ProText Mobility's stock price is $0.00485. ProText Mobility's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2014 was $-0.537. Therefore, ProText Mobility's PE Ratio (TTM) for today is At Loss.


ProText Mobility  (OTCPK:TXTM) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

ProText Mobility's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.00485/-0.537
=At Loss

ProText Mobility's share price for today is $0.00485.
ProText Mobility's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.537.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


ProText Mobility EV-to-FCF Related Terms


ProText Mobility EV-to-FCF Historical Data

* Premium members only.

The historical data trend for ProText Mobility's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProText Mobility EV-to-FCF Chart

ProText Mobility Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.30 -6.78 -4.63 -3.06 -4.57

ProText Mobility Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TXTM vs DRSV, YPPN, CYBF: EV-to-FCF Comparison

For the Biotechnology subindustry, ProText Mobility's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProText Mobility EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProText Mobility's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where ProText Mobility's EV-to-FCF falls into.



ProText Mobility EV-to-FCF Calculation

ProText Mobility's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=42.637/-0.706
=-60.39

ProText Mobility's current Enterprise Value is $42.64 Mil.
ProText Mobility's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-FCF →
What does a EV-to-FCF of -60.39 mean?
ProText Mobility (TXTM) has a EV-to-FCF of -60.39 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ProText Mobility and its competitors.
Is ProText Mobility's EV-to-FCF too high?
ProText Mobility's current EV-to-FCF is -60.39.
How does ProText Mobility's EV-to-FCF compare to DRSV and YPPN?
ProText Mobility's EV-to-FCF of -60.39 can be compared against companies in the Biotechnology industry. The industry median EV-to-FCF is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ProText Mobility and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProText Mobility's current EV-to-FCF is -60.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProText Mobility stock overvalued right now?
ProText Mobility (TXTM) has a current EV-to-FCF of -60.39. The current EV-to-FCF is -60.39. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For ProText Mobility (TXTM), the current EV-to-FCF is -60.39 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProText Mobility Business Description

Address One West Las Olas Boulevard, Suite 500, Fort Lauderdale, FL, USA, 33301
ProText Mobility Inc is a Biotech Company developing a Hemp/CBD-Cannabis medicines platform for the legal cannabis industry, using proprietary live plant extraction processes and technologies. Protext has engaged in the research, testing, and development of bioavailable botanical products, all-natural ingredients formulated for nutraceuticals and pharmaceutical applications through proprietary live plant extraction technology.